Cediranib (RECENTIN™, AZD2171)
Drug timelines are a Plus or Pro feature.
1 regulatory and trial event tracked for Cediranib (RECENTIN™, AZD2171), covering 2012-12-17 to 2012-12-17. Get the full timeline:
Most recent: Clinical Trial Update: Phase I Safety and Tolerability Study of Cediranib (RECENTIN™, AZD2171) in Combination With Chemo in First Line Lung Cancer Patients [Phase 1]